Cleveland, OHNCT06891456Now EnrollingIRB Ready

Ventricular Tachycardia Clinical Trial in Cleveland, OH

Access cutting-edge ventricular tachycardia treatment through this clinical trial at a research site in Cleveland. Study-provided care at no cost to qualified participants.

Sponsored by Pasquale Santangeli

Quick Self-Assessment

See if you qualify for this Cleveland location

Preparing your pre-screening questions…

Expert Care in Cleveland

Access ventricular tachycardia specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related ventricular tachycardia treatment provided free

Apply for This Cleveland Location

Check if you qualify for this ventricular tachycardia clinical trial in Cleveland, OH

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Cleveland

    Convenient for OH residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Cleveland site if eligible
  4. 4Begin participation

About This Ventricular Tachycardia Study in Cleveland

ASCEND is a randomized controlled open-label pilot study evaluating the safety and effectiveness of pulsed field ablation (PFA) with the novel FARAPOINT catheter compared to the standard radiofrequency (RFA) ablation with ThermoCool ST/FlexAbility SE/ThermoCool ST SF/TactiFlex SE of ventricular tachycardia (VT) in the patients with ischemic cardiomyopathy and implantable cardioverter-defibrillator (ICD). The study hypothesis is that the PFA ablation is more efficient compared to the RFA technique but retains a comparable safety profile.

Sponsor: Pasquale Santangeli

Who Can Participate

Inclusion Criteria

must meet all of the following:
Age ≥18 years.
Ischemic heart disease with prior myocardial infarction.
Left ventricular ejection fraction ≥20% estimated by transthoracic echocardiography (TTE) within 90 days prior to enrollment.
Documented sustained monomorphic VT with any of the following characteristics:
≥2documented episodes in patients with implantable cardioverter defibrillators (ICD)
≥1 documented episode(s) in patients without ICD
Recurrent VT despite antiarrhythmic medications (ineffective, contraindicated or not tolerated) or ICD interventions
Provision of signed and dated informed consent form.
Stated willingness to comply with all study procedures and availability for the duration of the study.

Exclusion Criteria

any of the following:
Unable to provide informed consent.
Idiopathic VT.
Mobile LV thrombus.
Acute coronary syndrome within the preceding 2 months (if incessant VT ≥1 month before enrollment).
Comorbidity likely to limit survival to \<12 months
New York Heart Association class IV heart failure.
Estimated glomerular filtration rate \<30 ml/min/1.73m2.
Thrombocytopenia or coagulopathy.
Contraindication to heparin.
Pregnancy or lactation.
Cardiac surgery within the past 2 months.
Active infection.
Clinical, laboratory or imaging evidence of active ischemia.
Severe left heart valvular heart disease (aortic/mitral stenosis or regurgitation).
Any concomitant congenital heart disease.
Prior catheter or surgical ablation of VT within the past 2 months.
Anticipated need for epicardial mapping and ablation.
For individuals with no pre-existing ICD: Ineligibility for an ICD implant.
Pre-existing LVAD or other hemodynamic assist device
Present mechanical heart valve
cardiogenic shock unless it is due to incessant VT

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Cleveland?

Yes, this clinical trial (NCT06891456) has an active research site in Cleveland, OH that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Ventricular Tachycardia Treatment Options in Cleveland, OH

If you're searching for ventricular tachycardia treatment options in Cleveland, OH, this clinical trial (NCT06891456) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Cleveland research site is actively enrolling participants for this clinical trial. You'll receive care from experienced ventricular tachycardia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all ventricular tachycardia clinical trials near you to find additional studies recruiting in your area.

More Interstitial Cystitis Trials in Cleveland, OH

See all interstitial cystitis clinical trials recruiting in Cleveland — not just this study.

Browse Interstitial Cystitis Trials in Cleveland →

Browse More Trials by Condition

Interstitial Cystitis TrialsAll Conditions →

Ready to Join in Cleveland?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Cleveland, OH